In vitro degradation of novel bioactive polycaprolactone—20% tricalcium phosphate composite scaffolds for bone engineering

Our group recently fabricated novel 3D polycaprolactone—20% tricalcium phosphate (PCL-TCP) composite scaffolds for applications in bone engineering. The bioactivity of such synthetic biomaterials can be evaluated by examining its ability to initiate the formation of apatite on its surface when immersed in simulated body fluids (SBF). In this study, the in vitro degradation behaviors of these scaffolds were systematically monitored for varying time periods of 1, 7, 14, 21 and 28 days post-immersion in SBF at 37 °C. Weight loss and water absorption of the samples indicated that PCL-TCP scaffolds were only slowly degraded. Biochemical assays and pH measurements revealed that hydroxyapatite, the main inorganic constituent of bone, commenced to form on the surface of the scaffolds after 17 days of immersion in SBF. Von Kossa assays demonstrated that calcium deposits increased progressively on the surface of the scaffolds after soaking in SBF for 2 weeks. Scanning electron microscopy verified the surface crystallization of the apatite layer formed over the entire period of time. In conclusion, the synergy of PCL with TCP in a composite scaffold confers both bioresorbability as well as bioactivity that offer an exciting approach for bone regeneration purposes.